fda approves semaglutide weight-loss drug Wegovy to reduce heart-disease risks Wegovy Pill FDA Approved: What

The GLP-1 class of drugs has revolutionized the treatment of diabetes and obesity while also reducing cardiovascular adverse events

Providing adolescents with obesity another option Wegovy is the only once-weekly injectable GLP-1 RA indicated to reduce excess body weight and maintain weight reduction long term in combination with diet and exercise in adolescents with obesity aged 12 years and older 3 The safety and effectiveness of Wegovy injection have not been established in pediatric patients to reduce the risk of major adverse CV events or to reduce excess body weight and maintain weight reduction long term in those less than 12 years of age

The lead line is a scalloped band of brown-to-black discoloration along the free gingival margin of the teeth, the result of precipitation of lead by sulfide-producing bacteria in the gingival crevice

As these weight-loss medications have gained popularity potentially helping obesity rates drop for the first time in a decade theyve also seemed to reduce patients alcohol use, too